Related Experiment Videos
Detection of COPB2 as a KRAS synthetic lethal partner through integration of functional genomics screens
Eleni G Christodoulou1,2, Hai Yang3, Franziska Lademann4
1Biotechnology Center, TU Dresden, Germany.
Abstract:
Mutated KRAS plays an important role in many cancers. Although targeting KRAS directly is difficult, indirect inactivation via synthetic lethal partners (SLPs) is promising. Yet to date, there are no SLPs from high-throughput RNAi screening, which are supported by multiple screens. Here, we address this problem by aggregating and ranking data over three independent high-throughput screens. We integrate rankings by minimizing the displacement and by considering established methods such as RIGER and RSA.Our meta analysis reveals COPB2 as a potential SLP of KRAS with good support from all three screens. COPB2 is a coatomer subunit and its knock down has already been linked to disabled autophagy and reduced tumor growth. We confirm COPB2 as SLP in knock down experiments on pancreas and colorectal cancer cell lines.Overall, consistent integration of high throughput data can generate candidate synthetic lethal partners, which individual screens do not uncover. Concretely, we reveal and confirm that COPB2 is a synthetic lethal partner of KRAS and hence a promising cancer target. Ligands inhibiting COPB2 may, therefore, be promising new cancer drugs.
Insights
Researchers identified COPB2 as a synthetic lethal partner (SLP) for KRAS mutations in cancer. This discovery offers a new therapeutic strategy by indirectly targeting KRAS through COPB2 inhibition, potentially leading to novel cancer drugs.
Area of Science:
- Oncology
- Molecular Biology
- Genetics
Background:
- Mutated KRAS is a key driver in numerous cancers.
- Directly targeting KRAS is challenging, making indirect strategies like synthetic lethality promising.
- Existing high-throughput screens lack validated synthetic lethal partners (SLPs) for KRAS supported by multiple studies.
Purpose of the Study:
- To identify novel synthetic lethal partners (SLPs) for KRAS by integrating data from multiple high-throughput RNAi screens.
- To validate COPB2 as a potential SLP for KRAS.
- To explore COPB2 as a potential therapeutic target in KRAS-mutated cancers.
Main Methods:
- Aggregated and ranked data from three independent high-throughput RNAi screens.
- Integrated screening data using methods like minimizing displacement, RIGER, and RSA.
- Performed knockdown experiments in pancreatic and colorectal cancer cell lines to validate findings.
Main Results:
- A meta-analysis of screening data identified COPB2 as a strong candidate SLP for KRAS.
- COPB2 knockdown showed synthetic lethality with KRAS mutations in cancer cell lines.
- COPB2, a coatomer subunit, has known links to impaired autophagy and reduced tumor growth.
Conclusions:
- Consistent integration of high-throughput screening data can uncover novel therapeutic targets missed by individual screens.
- COPB2 is confirmed as a synthetic lethal partner of KRAS, representing a promising new target for cancer therapy.
- Inhibitors targeting COPB2 could be developed into effective new cancer drugs for KRAS-mutated tumors.